ADDERALL XR 5 MG
MIXED SALTS AMPHETAMINE : 5 MG · DIN 02248808 · TAKEDA CANADA INC
Health Canada status: MARKETED
What is ADDERALL XR?
ADDERALL XR 5 MG contains MIXED SALTS AMPHETAMINE : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02248808, held by TAKEDA CANADA INC, supplied as CAPSULE (EXTENDED RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 21-Dec-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ADDERALL XR used for?
ADDERALL XR (mixed salts amphetamine extended-release capsules) is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in: Children (6 – 12 years of age), Adolescents (13 – 17 years of age), Adults (18 years of age or older). ADDERALL XR is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02248808 |
|---|---|
| Brand name | ADDERALL XR |
| Generic / active ingredient | MIXED SALTS AMPHETAMINE : 5 MG |
| Manufacturer | TAKEDA CANADA INC |
| Strength | 5 MG |
| Dosage form | CAPSULE (EXTENDED RELEASE) |
| Route of administration | ORAL |
| Schedule | CONTROLLED DRUGS (CDSA I) |
| ATC code | N06BA01 AMFETAMINE |
| AHFS class | 28:20.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 21-Dec-2020 |
| Original market date | 2004-01-30 00:00:00 |
How is it administered?
Once daily in the morning. Children (6-12): start 10 mg, max 30 mg/day. Adolescents/Adults: start 10 mg, usual max 20 mg/day (rarely 30 mg). Swallow whole or sprinkle on applesauce.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
null
How is it supplied?
ADDERALL XR 5 mg Capsules: Bottles of 100. ADDERALL XR 10 mg Capsules: Bottles of 100. ADDERALL XR 15 mg Capsules: Bottles of 100. ADDERALL XR 20 mg Capsules: Bottles of 100. ADDERALL XR 25 mg Capsules: Bottles of 100. ADDERALL XR 30 mg Capsules: Bottles of 100.
Contraindications
Hypersensitivity to amphetamines; advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; glaucoma; agitated states; history of drug abuse.
Warnings and precautions
Potential for abuse/misuse. Misuse may cause serious cardiovascular events/sudden death. Risk of QTc prolongation, peripheral vasculopathy, and suppression of growth in children.
What can be used instead?
Other Canadian products sharing ATC code N06BA01 AMFETAMINE. 22 of 41 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ADDERALL XR | 10 MG | CAPSULE (EXTENDED RELEASE) | TAKEDA CANADA INC | MARKETED | DIN 02248809 |
| ADDERALL XR | 15 MG | CAPSULE (EXTENDED RELEASE) | TAKEDA CANADA INC | MARKETED | DIN 02248810 |
| ADDERALL XR | 20 MG | CAPSULE (EXTENDED RELEASE) | TAKEDA CANADA INC | MARKETED | DIN 02248811 |
| ADDERALL XR | 25 MG | CAPSULE (EXTENDED RELEASE) | TAKEDA CANADA INC | MARKETED | DIN 02248812 |
| ADDERALL XR | 30 MG | CAPSULE (EXTENDED RELEASE) | TAKEDA CANADA INC | MARKETED | DIN 02248813 |
| APO-AMPHETAMINE XR | 10 MG | CAPSULE (EXTENDED RELEASE) | APOTEX INC | MARKETED | DIN 02445506 |
| APO-AMPHETAMINE XR | 15 MG | CAPSULE (EXTENDED RELEASE) | APOTEX INC | MARKETED | DIN 02445514 |
| APO-AMPHETAMINE XR | 20 MG | CAPSULE (EXTENDED RELEASE) | APOTEX INC | MARKETED | DIN 02445522 |
| APO-AMPHETAMINE XR | 25 MG | CAPSULE (EXTENDED RELEASE) | APOTEX INC | MARKETED | DIN 02445530 |
| APO-AMPHETAMINE XR | 30 MG | CAPSULE (EXTENDED RELEASE) | APOTEX INC | MARKETED | DIN 02445549 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.